Disease: Mantle cell lymphoma
- An atlas of cells in the human tonsil
- Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders
- Anlotinib Inhibiting Mantle Cell Lymphoma Proliferation and Inducing Apoptosis through PI3K/AKT/mTOR Pathway
- Assessment of the effects of amphiphilic poly (N-vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos
- Assessment of the effects of amphiphilic poly (N‑vinylpyrrolidone) nanoparticles loaded with bortezomib on glioblastoma cell lines and zebrafish embryos
- Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
- Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer
- B-cell lymphoma research in Malaysia - A narrative review
- B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression
- Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma
- Blastoid Mantle Cell Lymphoma Presenting as an Oropharyngeal Mass
- Blastoid Variant of Mantle Cell Lymphoma with Extranodal Presentation and Aberrant CD10 Expression
- BTK Inhibitors in CLL : Second Generation Drugs and Beyond
- CAD204520 Targets <em>NOTCH1</em> PEST Domain Mutations in Lymphoproliferative Disorders
- CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists
- CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
- Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases
- CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE
- Clinical features and prognostic analysis of the blastoid variant of mantle cell lymphoma: An analysis of 20 patients from two centers
- Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma
- Clinical Management of Mantle Cell Lymphoma With Concurrent Vascular Complications: A Case Report
- CLO24-086: The Effect of TBI-Based Conditioning Regimen on Recurrence and Transplant-Related Mortality Among Patients With Mantle Cell Lymphoma Who Received Autologous Bone Marrow Transplant
- Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement
- Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib - Case report
- Covalent docking-driven virtual screening of extensive small-molecule libraries against Bruton tyrosine kinase for the identification of highly selective and potent novel therapeutic candidates
- Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion
- Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma
- Diagnosis of chronic B-cell lymphoproliferative disease in peripheral blood = how machine learning may help to the interpretation of flow cytometry data
- Does BTKi improve CAR T-cell therapy in MCL?
- Early CAR(-) CD4(+) T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma
- Effect of Chlorambucil Combined with Ibrutinib on Mantle Cell Lymphoma Cell Line Jeko-1 and Its Related Mechanism
- Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell Lymphoma
- Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement
- Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
- Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
- Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma
- FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis
- Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis
- Frontline Treatment of Mantle Cell Lymphoma
- Genetically determined telomere length as a risk factor for hematological malignancies: evidence from Mendelian randomization analysis
- Genetically predicted telomere length and the risk of 11 hematological diseases: a Mendelian randomization study
- Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021
- Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
- Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systema
- Histopathological staging and differential diagnosis of marginal zone lymphoma of gastric mucosa-associated lymphoid tissue
- Identification and assessment of new PIM2 inhibitors for treating hematologic cancers: A combined approach of energy-based virtual screening and machine learning evaluation
- IgD expression in various immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma in children
- Incidence and survival of second primary non-Hodgkin lymphoma: A Surveillance, Epidemiology, and End Results-based cohort study
- Inhibition of Autophagy Augments the Anticancer Activity of KPT-330 in Mantle Cell Lymphoma Cells
- Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
- Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more
- LINK-A: unveiling its functional role and clinical significance in human tumors
- Management of relapsed/refractory mantle cell lymphoma
- Mantle Cell Lymphoma Presenting as Cholecystitis and Nephromegaly
- Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions
- Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
- Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
- Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
- MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases
- Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study
- Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey
- Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
- Novel BRAF N581S mutation in mantle cell lymphoma
- Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients
- Ocular and nasopharyngeal manifestations of mantle cell lymphoma: a multidisciplinary approach to diagnosis and treatment challenges
- Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma
- Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021
- Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
- Persistent COVID-19: a case report of an immunocompromised patient and a literature review
- Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma
- Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
- Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies
- PrecisionLymphoNet: Advancing Malignant Lymphoma Diagnosis via Ensemble Transfer Learning with CNNs
- PRMT5 activates lipid metabolic reprogramming via MYC contributing to the growth and survival of mantle cell lymphoma
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
- REALM study: A retrospective evaluation of treatment patterns in patients with mantle cell lymphoma in a routine single private practice in Brazil
- Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
- Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas
- Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma
- SENP3 Promotes Mantle Cell Lymphoma Development through Regulating Wnt10a Expression
- Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
- Simultaneous Determination of Ibrutinib, Dihydroxydiol Ibrutinib, and Zanubrutinib in Human Plasma by Liquid Chromatography-Mass Spectrometry/Mass Spectrometry
- SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
- SOX11 expression is restricted to EBV-negative Burkitt lymphoma and associates with molecular genetic features
- SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma
- SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma
- Survival Outcomes of Patients with Mantle Cell Lymphoma: A Retrospective, 15-Year, Real-Life Study
- Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms
- Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma
- Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma
- The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
- The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma
- The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma
- The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma
- The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
- TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present
- Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma
- Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma
- Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario
- Unraveling MCL biology to understand resistance and identify vulnerabilities